UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Rennova Health, Inc.

(Name of Issuer)

Common Stock, $.01 par value

(Title of Class of Securities)

759757 10 7

(CUSIP Number)

Thomas Francis Mendolia

400 South Australian Avenue, 8^th Floor

West Palm Beach, Florida 33401

(561) 855-1626

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 2, 2016

(Date of Event which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1. Security and Issuer

This Amendment No. 1 to Schedule 13D amends the Statement on Schedule 13D, dated November 2, 2015, with respect to the Common Stock, $0.01 par value per share (the "Shares"), of Rennova Health, Inc., a Delaware corporation (the "Issuer"), filed by Dr. Thomas Francis Mendolia. Except as expressly amended below, the Schedule 13D, dated November 2, 2015, remains in effect.

Item 2. Identity and Background

Item 2 is hereby amended to include the following:

Dr. Mendolia is an employee of the Issuer and is a member of the scientific advisory committee of the Issuer.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended to include the following:

This Amendment No. 1 to Schedule 13D is being filed to report the grant to Dr. Mendolia on May 2, 2016 of an aggregate 2,020,000 options to purchase a like number of Shares of the Issuer. With respect to such options, 1,000,000 options are currently exercisable through December 31, 2017, at an exercise price of $5.00 per Share, 1,000,000 options are currently exercisable through December 31, 2022, at an exercise price of $10.00 per Share, and 20,000 options have an exercise price of $1.00 per share, which vest as follows: 5,000 upon the date of grant, 5,000 on June 30, 2016, 5,000 on September 30, 2016, and 5,000 on December 31, 2016, subject to Dr. Mendolia's attendance at meetings of the Issuer's scientific advisory committee.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended to include the following:

As of May 2, 2016, Dr. Mendolia may be deemed to beneficially own 3,875,659 Shares (or approximately 23.1% of the total number of Shares outstanding), which consists of (i) 1,855,659 Shares and (ii) 2,020,000 stock options owned of record by Dr. Mendolia, as described in Item 3. above, to purchase a like number of Shares; as to which Dr. Mendolia has sole dispositive and voting power. Such Shares do not include 1,000 shares of the Issuer's Series B Convertible Preferred Stock, owned of record by Dr. Mendolia.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.